Cns Pharmaceuticals Inc (CNSP) Stock Price, Quote & News

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 800-946-9185

Website: www.cnspharma.com

Address:

2100 West Loop South, Suite 900, Houston, United States

TheUnmaker Sep. 9 at 12:22 AM

$CNSP I like the stock! Profits will shift into $BB

0 · Reply

artinB Sep. 8 at 5:25 PM

@SpartanVI check out $CNSP 25$ cash value, float is less than 500k

0 · Reply

artinB Sep. 8 at 5:03 PM

@Paraboljoker check out $CNSP 25$ cash value, float is less than 500k

0 · Reply

artinB Sep. 8 at 3:51 PM

$CNSP holding full position, our day will come soon, 25$ cash value , float is less than 500k

0 · Reply

kl7777 Sep. 8 at 2:46 PM

$CNSP Visit cns_pharma on X account for the latest presentation. Not much volume and posts again today. Add even few shares and hold.

0 · Reply

Herbgator Sep. 8 at 12:59 PM

$CNSP Take a look at John’s presentation…not much we didn’t already know 6-months ago but just the charts are at least a lot sexier. Re. Berubicin, their hope in GBM now seems pinned on to trying to obtain approval as a 3rd line behind TMZ and Lomustine and they’re optimistic within the new FDA. Additionally they continue to float the universal opportunity for the drug beyond GBM. IMHO

0 · Reply

TheUnmaker Sep. 6 at 12:53 PM

$CNSP

0 · Reply

NetworkNewsWire Sep. 5 at 7:39 PM

NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers $CNSP https://ibn.fm/u2NRX #biomedstocks #Cancers

0 · Reply

kl7777 Sep. 5 at 2:31 PM

$CNSP Not much posts here. Buy and hold.

0 · Reply

kl7777 Sep. 4 at 1:55 PM

$CNSP Trading volume is only around 1,000 now. More people should buy even few shares and hold until $20.

0 · Reply

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 15, 2025, 8:05 AM EDT - 24 days ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 9:15 AM EDT - 25 days ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 22, 2025, 8:45 AM EDT - 6 weeks ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 18, 2025, 8:00 AM EDT - 7 weeks ago

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 9, 2025, 9:32 AM EDT - 2 months ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jun 24, 2025, 9:15 AM EDT - 2 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 5, 2025, 8:05 AM EDT - 3 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

May 16, 2025, 8:05 AM EDT - 4 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:35 AM EDT - 4 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 7:00 AM EDT - 4 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

Apr 1, 2025, 8:05 AM EDT - 5 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Mar 25, 2025, 12:05 PM EDT - 5 months ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 8:00 AM EDT - 5 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Feb 26, 2025, 9:05 AM EST - 6 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 20, 2025, 9:00 AM EST - 7 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 19, 2025, 9:00 AM EST - 7 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 18, 2025, 9:00 AM EST - 7 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 10, 2025, 8:00 AM EST - 7 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Dec 5, 2024, 9:10 AM EST - 9 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Nov 25, 2024, 9:00 AM EST - 10 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 18, 2024, 8:55 AM EST - 10 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 15, 2024, 9:10 AM EST - 10 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 9:15 AM EST - 11 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 1, 2024, 9:00 AM EDT - 11 months ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Oct 23, 2024, 2:50 PM EDT - 11 months ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 10, 2024, 9:00 AM EDT - 11 months ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 8, 2024, 9:15 AM EDT - 11 months ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 16, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 1, 2024, 5:00 PM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

GILD REVB ZLAB

Jan 29, 2024, 9:00 PM EST - 1 year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Jan 18, 2024, 8:45 AM EST - 1 year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 17, 2024, 8:45 AM EST - 1 year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Dec 18, 2023, 8:35 AM EST - 1 year ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

TheUnmaker Sep. 9 at 12:22 AM

$CNSP I like the stock! Profits will shift into $BB

0 · Reply

artinB Sep. 8 at 5:25 PM

@SpartanVI check out $CNSP 25$ cash value, float is less than 500k

0 · Reply

artinB Sep. 8 at 5:03 PM

@Paraboljoker check out $CNSP 25$ cash value, float is less than 500k

0 · Reply

artinB Sep. 8 at 3:51 PM

$CNSP holding full position, our day will come soon, 25$ cash value , float is less than 500k

0 · Reply

kl7777 Sep. 8 at 2:46 PM

$CNSP Visit cns_pharma on X account for the latest presentation. Not much volume and posts again today. Add even few shares and hold.

0 · Reply

Herbgator Sep. 8 at 12:59 PM

0 · Reply

TheUnmaker Sep. 6 at 12:53 PM

$CNSP

0 · Reply

NetworkNewsWire Sep. 5 at 7:39 PM

NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers $CNSP https://ibn.fm/u2NRX #biomedstocks #Cancers

0 · Reply

kl7777 Sep. 5 at 2:31 PM

$CNSP Not much posts here. Buy and hold.

0 · Reply

kl7777 Sep. 4 at 1:55 PM

$CNSP Trading volume is only around 1,000 now. More people should buy even few shares and hold until $20.

0 · Reply

Herbgator Sep. 4 at 3:50 AM

$CNSP Looks like the overwhelming majority of current outstanding shares are in the hands of these hedge funds who also have potential future warrants etc which if exercised could increase the os by approximately 1m shares. No wonder management no longer does stockholder q&a’s. IMHO.

0 · Reply

primecomm23 Sep. 3 at 5:25 PM

$CNSP Folks stacked the Bids not the Ask. LOL

0 · Reply

kl7777 Sep. 3 at 2:34 PM

$CNSP From the news, company is to present advancement in investment conference, located in NY from Sept 8th-10th. Some may disagree, but more should add shares at this low price to move up the price.

0 · Reply

NetworkNewsWire Sep. 2 at 5:44 PM

Study Finds Link Between Head Injuries and Elevated Brain Cancer Risk $CNSP https://ibn.fm/amPM5 #tinygems #cancer

0 · Reply

artinB Sep. 2 at 4:55 PM

$AUUD and $CNSP have all the ingredients to skyrocket

0 · Reply

artinB Sep. 2 at 4:20 PM

$CNSP look at $HWH this is what happens to the low float stocks, $CNSP has a float less than 500k

0 · Reply

kl7777 Sep. 2 at 2:59 PM

$CNSP Less than 10% traded so far, compared to 65 day avg volume. I think without volume, price would not change much so more should buy shares, including me.

0 · Reply

Armarium Aug. 31 at 8:10 PM

$CNSP How come the CEO John hasn’t been imprisoned yet?! Biggest fraudster ever…

0 · Reply

kl7777 Aug. 29 at 2:47 PM

$CNSP More should add shares at this low price.

0 · Reply

BigStonks42069420 Aug. 29 at 11:14 AM

$CNSP its actually insane that this stock was (at this current split) worth almost $4,000,000/share and is now worth $6. Thats actually not a joke lol

0 · Reply

MONSTER_MOVER_STOCKS Aug. 28 at 11:31 PM

$CNSP Watching this one. Giving off big gap up vibes. Current after-hours price is $6.39 on 8/28/25.

0 · Reply

artinB Aug. 28 at 5:11 PM

$CNSP soon will be 10-15$ 25$ cash value Float less than 500k

0 · Reply

Market Cap	3.56M
Revenue (ttm)	0.00
Net Income (ttm)	-14.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	19,900
Avg Vol	47,248
Day's Range	N/A - N/A
Shares Out	575,000.00
Stochastic %K	64%
Beta	2.61
Analysts	Hold
Price Target	$7.00